BRIEF-Mannkind Says Afrezza Available To Eligible Patients For $35 Or Less Per Month

MannKind Corporation

MannKind Corporation

MNKD

0.00

May 29 (Reuters) - MannKind Corp MNKD.O:

  • MANNKIND ANNOUNCES FDA APPROVAL OF AFREZZA®, THE FIRST AND ONLY INHALED MEALTIME INSULIN FOR USE IN CHILDREN AND ADOLESCENTS AGED 6 AND OLDER LIVING WITH DIABETES

  • MANNKIND - AFREZZA AVAILABLE TO ELIGIBLE PATIENTS FOR $35 OR LESS PER MONTH


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.